ClinicalTrials.gg
Not yet recruitingNCT07393932Updated Feb 6, 2026

MND Together: Phase 1

An observational study in MND (Motor Neurone DIsease), sponsored by University of Sheffield. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by University of Sheffield · Observational

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
287
Ages
18 Years and older
Sex
All
01

Study summary

This project consists of two workstreams, both of which will be mixed-methods and aim to develop a national UK picture of current care coordination for people with MND, including observations of barriers and facilitators. The studies will explore how care is transferred and communicated across MND specialist services to non-specialist community health settings.

In workstream 1, the researchers will conduct focus groups with people with MND, Carers, former Carers, Health and Social Care Professionals and managers and commissioners. These focus groups, alongside the analysis of routine data, will create a national picture of MND care and begin a behavioural diagnosis of the barriers and facilitators. In workstream 2, a multi-site ethnography study will be conducted, including observations, interviews, routine data, care plan and document review. This Workstream will observe how care is coordinated between specialist and non-specialist services and continue to explore barriers and facilitators that can not be identified through interviews.

02

Conditions studied

  • MND (Motor Neurone DIsease)

Keywords

  • MND
  • Care coordination
  • health and social care
  • multidisciplinary care
  • community services
  • Motor Neurone Disease
  • Neurological conditions
  • ethnography
  • Amyotrophic lateral sclerosis (ALS)
  • Qualitative
03

In context

Amyotrophic Lateral Sclerosis

978 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 277 are open to participants now.

This study's planned enrollment of 287 is above the median of 108 across 265 observational studies indexed under Amyotrophic Lateral Sclerosis.

Browse Amyotrophic Lateral Sclerosis studies →

Lead sponsor

University of Sheffield is the lead sponsor of 75 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

People attending MND specialist centres and non specialist community services

Eligibility criteria

WS1

Inclusion Criteria:

  • Person with MND, carers, former carers, Health and Social Care Professionals, managers and commissioners
  • Ability to engage in focus group or interview or email interview

Exclusion Criteria:

  • no exclusion criteria

WS2

Inclusion Criteria:

  • Person with MND, carers, former carers, Health and Social Care Professionals, managers and commissioners
  • Ability to engage in an observations and interviews

Exclusion Criteria:

  • no exclusion criteria
05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
287 participants (estimated)
Patient registry
No

Interventions

  • OtherNot applicable- observational study

    MND-Together tool will be informed by the findings from this study

06

What researchers measure

Primary outcomes

  1. Number of barriers and facilitators for capability, opportunity and motivation (COM-B)

    Time frame: February 2026- February 2027

07

Study locations

1 site
  • School of Medicine and Populational Health
    Sheffield, Yorkshire, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — The pseudo-anonymised data, and analysis output will be uploaded to the University of Sheffield data repository, ORDA, and stored for 10 years as per the University of Sheffield Retention Schedule. The data will be embargoed until the study has been published in a peer-reviewed journal and will be available thereafter to other researchers upon reasonable request to the CI.

Time frame: After the study has been published in a peer-review journal and it will be kept on the data repository for 10 years

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Dec 2026, 10 months later.

Of 127 non-industry observational studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 125. This study's planned 10 months is below that.

Counting every sponsor, half of 136 studies reached it within 64 months; a quarter within 29 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Feb 6, 2026
StartEst.
Feb 2026
Primary completionEst.
Dec 2026
CompletionEst.
Feb 2027
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07393932
Lead sponsor
University of Sheffield
Collaborators
National Institute for Health Research, United Kingdom, Liverpool John Moores University, Sheffield Teaching Hospitals NHS Foundation Trust, Cornwall Partnership NHS Foundation Trust, Northern Lincolnshire and Goole Hospitals NHS Foundation Trust, Dementias Platform UK, NIHR HealthTech Research Centre, Swansea Bay University Health Board
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Feb 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Feb 6, 2026

Study contacts

Liam Knox, PhD
Contact
l.knox@sheffield.ac.uk
+441142222291
Chris McDermott, MBChB, FRCP, PhD
Contact
c.j.mcdermott@sheffield.ac.uk
+44 1142222295
Liam Knox, PhD
principal investigator · University of Sheffield
Chris McDermott, MBChB, FRCP, PhD
principal investigator · University of Sheffield

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion